质子抑制剂的使用是否会增加消化系统瘤的风险? :一个双样本的门德尔随机化研究
Ruiqi Zhao1, Sen Lin1, Mengyao Han2
1The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China.
Medicine
|November 14, 2023
概括
根据孟德尔的随机化研究,使用质子抑制剂 (PPI) 显示出对胰腺癌的保护作用. 在PPI和其他消化系统瘤之间没有发现因果关系.
科学领域:
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
- 遗传流行病学遗传流行病学
背景情况:
- 质子抑制剂 (PPI) 广泛用于与酸有关的胃肠道疾病.
- 人们对个人消化剂对消化系统健康的潜在长期影响存在担忧.
- 了解PPI使用和癌症之间的因果关系对于患者安全至关重要.
研究的目的:
- 调查使用质子抑制剂 (PPI) 与发展16种消化系统瘤的风险之间的潜在因果关系.
- 利用强大的遗传流行病学方法来评估这种关联.
主要方法:
- 采用了一种双样本的门德尔随机化 (MR) 研究设计.
- 与梅使用 (一种常见的PPI) 相关的遗传变异被用作仪器变量.
- 在欧洲人群 (英国生物库,芬兰生物库) 中进行的大规模全基因组关联研究 (GWAS) 的数据使用逆方差加权 (IVW),MR-Egger和加权中位数方法进行了分析.
主要成果:
- 门德尔随机化分析显示,甲醇对胰腺恶性瘤的使用具有显著的保护性因果作用 (IVW OR:4.33E-05,P=0.03).
- 在PPI使用与其他15种消化系统瘤之间没有观察到显著的因果关系.
- 灵敏度分析证实了研究结果的可靠性,没有发现显著的异质性或性.
结论:
- 质子抑制剂 (PPI) 的使用似乎是胰腺恶性瘤的保护因素.
- 该研究没有发现PPI使用与其他消化系统瘤之间存在因果关系的证据.
- 这些发现有助于了解PPI与消化道癌症相关的安全性.
相关概念视频
Peptic Ulcer Disease I: Introduction
179
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
179
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
438
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
438
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
458
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
458
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
438
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
438
Peptic Ulcer Disease IV: Management
96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
605
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
605


